ArticleBMC cardiovascular disorders2025
Assisting significance of lncRNA ASB16-AS1 in the early detection and prognosis prediction of patients with deep venous thrombosis.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical significance of lncRNA GAS5 in deep vein thrombosis and its mechanism of action on vascular endothelial damage.BMC cardiovascular disorders · 2026Article
- LncRNA PVT1 targets miR-143-3p to modulate endothelial cell function and thereby participate in deep vein thrombosis (DVT) of the lower limbs.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeep venous thrombosis (DVT) is a kind of vascular obstruction, that commonly and widely occurs in lower limbs. Due to the lack of obvious symptoms in the early stage, the rate of misdiagnosis and missed diagnosis is high. This study evaluated the expression and significance of lncRNA ASB16-AS1 (ASB16-AS1) in DVT aiming to identify a novel biomarker for its screening and monitoring.
methodsThere were 77 DVT patients and 62 healthy individuals included in this study. Plasma ASB16-AS1 level was evaluated using PCR and compared between DVT and healthy groups. The diagnostic and prognostic values of ASB16-AS1 were assessed with ROC and Cox analyses. The correlation of ASB16-AS1 with patients' conditions, inflammation, and oxidative stress was evaluated by Spearman correlation analysis.
resultsASB16-AS1 was significantly upregulated in DVT (P < 0.001), which could discriminate DVT patients from healthy individuals with high sensitivity and specificity (AUC of ROC = 0.858). Increased ASB16-AS1 was associated with the incidence of complications (P = 0.033) and especially for pulmonary embolism in patients (P = 0.029). ASB16-AS1 was negatively correlated with prothrombin time (PT, r = -0.763), antithrombin level (AT, r = -0.711), and international normalized ratio (INR, r = -0.764), and showed positive correlation with fibrinogen (FIB, r = 0.793) and D-dimer (D-D, r = 0.731). Additionally, ASB16-AS1 was positively correlated with pro-inflammation cytokines (r
conclusionUpregulated ASB16-AS1 was identified as a diagnostic and prognostic biomarker of DVT and was closely associated with inflammation and oxidative stress during DVT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.